124 related articles for article (PubMed ID: 3830174)
41. Effect of saposins A and C on the enzymatic hydrolysis of liposomal glucosylceramide.
Vaccaro AM; Tatti M; Ciaffoni F; Salvioli R; Barca A; Scerch C
J Biol Chem; 1997 Jul; 272(27):16862-7. PubMed ID: 9201993
[TBL] [Abstract][Full Text] [Related]
42. The assay of glucocerebrosidase activity using the natural substrata.
Strasberg PM; Lowden JA
Clin Chim Acta; 1982 Jan; 118(1):9-20. PubMed ID: 7053909
[TBL] [Abstract][Full Text] [Related]
43. Further studies on the reconstitution of glucosylceramidase activity by Sap C and anionic phospholipids.
Salvioli R; Tatti M; Ciaffoni F; Vaccaro AM
FEBS Lett; 2000 Apr; 472(1):17-21. PubMed ID: 10781797
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the multiple forms of Gaucher spleen sphingolipid activator protein 2.
Paton BC; Poulos A
Biochem J; 1988 Aug; 254(1):77-84. PubMed ID: 3178760
[TBL] [Abstract][Full Text] [Related]
45. Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells.
Rijnboutt S; Aerts HM; Geuze HJ; Tager JM; Strous GJ
J Biol Chem; 1991 Mar; 266(8):4862-8. PubMed ID: 1848227
[TBL] [Abstract][Full Text] [Related]
46. Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue.
Pentchev PG; Brady RO; Blair HE; Britton DE; Sorrell SH
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3970-3. PubMed ID: 29293
[TBL] [Abstract][Full Text] [Related]
47. Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with type I, type II, and type III Gaucher disease.
Beutler E; Kuhl W
Proc Natl Acad Sci U S A; 1986 Oct; 83(19):7472-4. PubMed ID: 3463977
[TBL] [Abstract][Full Text] [Related]
48. The binding of glucosylceramidase to glucosylceramide is promoted by its activator protein.
Vaccaro AM; Muscillo M; Salvioli R; Tatti M; Gallozzi E; Suzuki K
FEBS Lett; 1987 Jun; 216(2):190-4. PubMed ID: 3582671
[TBL] [Abstract][Full Text] [Related]
49. Purification and characterization of bovine brain glucocerebrosidase.
Reddy PU; Murray GJ; Barranger JA
Biochem Med; 1985 Apr; 33(2):200-10. PubMed ID: 4004822
[TBL] [Abstract][Full Text] [Related]
50. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
van Weely S; van den Berg M; Barranger JA; Sa Miranda MC; Tager JM; Aerts JM
J Clin Invest; 1993 Mar; 91(3):1167-75. PubMed ID: 8450045
[TBL] [Abstract][Full Text] [Related]
51. Interaction of saposins, acidic lipids, and glucosylceramidase.
Morimoto S; Kishimoto Y; Tomich J; Weiler S; Ohashi T; Barranger JA; Kretz KA; O'Brien JS
J Biol Chem; 1990 Feb; 265(4):1933-7. PubMed ID: 2298731
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and processing of sphingolipid activator protein-2 (SAP-2) in cultured human fibroblasts.
Fujibayashi S; Wenger DA
J Biol Chem; 1986 Nov; 261(32):15339-43. PubMed ID: 3771578
[TBL] [Abstract][Full Text] [Related]
53. Purification of human placental glucocerebrosidase using a two-step high-performance hydrophobic and gel permeation column chromatography method.
Choy FY
Anal Biochem; 1986 Aug; 156(2):515-20. PubMed ID: 2429587
[TBL] [Abstract][Full Text] [Related]
54. Qualitative characteristics of the beta-glucosidase isozymes.
Choy FY; Davidson RG
Prog Clin Biol Res; 1982; 95():415-41. PubMed ID: 6812079
[No Abstract] [Full Text] [Related]
55. Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation.
Aerts JM; Schram AW; Strijland A; van Weely S; Jonsson LM; Tager JM; Sorrell SH; Ginns EI; Barranger JA; Murray GJ
Biochim Biophys Acta; 1988 Mar; 964(3):303-8. PubMed ID: 3349099
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene.
Schnabel D; Schröder M; Fürst W; Klein A; Hurwitz R; Zenk T; Weber J; Harzer K; Paton BC; Poulos A
J Biol Chem; 1992 Feb; 267(5):3312-5. PubMed ID: 1371116
[TBL] [Abstract][Full Text] [Related]
57. Sphingolipid hydrolase activator proteins and their precursors.
Sano A; Hineno T; Mizuno T; Kondoh K; Ueno S; Kakimoto Y; Inui K
Biochem Biophys Res Commun; 1989 Dec; 165(3):1191-7. PubMed ID: 2610686
[TBL] [Abstract][Full Text] [Related]
58. Interaction of activating protein and surfactants with human liver hexosaminidase A and GM2 ganglioside.
Hechtman P; Kachra Z
Biochem J; 1980 Mar; 185(3):583-91. PubMed ID: 7387624
[TBL] [Abstract][Full Text] [Related]
59. Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase.
Weiler S; Kishimoto Y; O'Brien JS; Barranger JA; Tomich JM
Protein Sci; 1995 Apr; 4(4):756-64. PubMed ID: 7613473
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and characterization of a bioactive 82-residue sphingolipid activator protein, saposin C.
Weiler S; Carson W; Lee Y; Teplow DB; Kishimoto Y; O'Brien JS; Barranger JA; Tomich JM
J Mol Neurosci; 1993; 4(3):161-72. PubMed ID: 8292489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
